Drilldown: Medicines
Appearance
Medicines > bioavailability
:
~100% both components
or
~80% (oral)'"`UNIQ--ref-00000027-QINU`"'
or
None 
:
~100% both components
or
~80% (oral)'"`UNIQ--ref-00000027-QINU`"'
or
None 
Use the filters below to narrow your results.
generic:
brand:
classes:
Research material (131) ·
Classic Psychedelic (69) ·
Stimulant (43) ·
Opioid (29) ·
Sedative-hypnotic (29) ·
Tryptamine (26) ·
Phenethylamine (25) ·
Botanical (23) ·
Benzodiazepine (22) ·
Anticonvulsant (19) ·
Dissociative (19) ·
Plant Medicine (18) ·
Antidepressant (17) ·
Antiparkinsonian (16) ·
Antipsychotic (16) ·
Empathogen (16) ·
Analgesic (15) ·
Neuroleptic (15) ·
Cathinone (14) ·
Nootropic (13)
mechanism:
5-HT2A agonist (27) ·
GABAA positive allosteric modulator (22) ·
None (12) ·
Monoamine releasing agent (11) ·
CB1/CB2 agonist (7) ·
Potent mu-opioid receptor agonist (6) ·
Sodium channel blocker (6) ·
Dopamine/norepinephrine reuptake inhibitor (5) ·
GABAA potentiator; NMDA antagonist (5) ·
Phenothiazine D2 antagonist (5) ·
Potent 5-HT2A agonist (5) ·
5-HT1B/1D agonist (4) ·
LSD analogue; 5-HT2A agonist (4) ·
Mu-opioid receptor agonist (4) ·
Muscarinic receptor antagonist (4) ·
Prodrug of LSD; 5-HT2A agonist (4) ·
Selective norepinephrine reuptake inhibitor (4)
None (392) ·
Pain, cough, disquiet (1) ·
'"`UNIQ--vote-00000006-QINU`"' (5) ·
'"`UNIQ--vote-00000008-QINU`"', '"`UNIQ--vote-00000009-QINU`"' (8) ·
'"`UNIQ--vote-0000000C-QINU`"', '"`UNIQ--vote-0000000D-QINU`"', '"`UNIQ--vote-0000000E-QINU`"', '"`UNIQ--vote-0000000F-QINU`"' (1) ·
'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (3) ·
'"`UNIQ--vote-00000065-QINU`"' (1) ·
'"`UNIQ--vote-000000AD-QINU`"', '"`UNIQ--vote-000000AE-QINU`"' (1) ·
'"`UNIQ--vote-000003A0-QINU`"', '"`UNIQ--vote-000003A1-QINU`"' (1) ·
'"`UNIQ--vote-00000468-QINU`"' (1) ·
'"`UNIQ--vote-000004B9-QINU`"', '"`UNIQ--vote-000004BA-QINU`"', '"`UNIQ--vote-000004BB-QINU`"' (1) ·
'"`UNIQ--vote-0000069B-QINU`"', '"`UNIQ--vote-0000069C-QINU`"' (1) ·
'"`UNIQ--vote-00000747-QINU`"', '"`UNIQ--vote-00000748-QINU`"' (1) ·
'"`UNIQ--vote-0000081E-QINU`"' (1)
None (409) ·
0.5–1 oz (10–30 g) ground for psychoactive effect; far smaller for culinary use (1) ·
10 mg PO once daily; titrate to 20 mg/day after 1-2 weeks if needed (1) ·
20 mg PO once daily; titrate to 40 mg/day after 1 week if tolerated. Elderly (>60) and hepatic impairment: 20 mg/day ceiling (1) ·
5 mg PO (1) ·
A ''marduuf'' bundle (~50 g fresh leaves) chewed over a couple of hours (1) ·
A measured pour of absinthe diluted 5:1 with cold water over sugar (the louche ritual) (1) ·
Anxiety: 25-50 mg PO QID. Pruritus: 25 mg PO TID-QID. Insomnia: 25-50 mg PO at bedtime. Pediatric: 50-100 mg/day divided (1) ·
For patients already stable on memantine 28 mg/d + donepezil 10 mg/d, switch to one capsule daily of equivalent strength (1) ·
One cup (~40–60 mg caffeine; about half of brewed coffee) (1)
None (392) ·
7/10, 14/10, 21/10, 28/10 mg ER capsules (memantine ER / donepezil) (1) ·
A ''betel quid'': areca nut slice + betel leaf + slaked lime (calcium hydroxide) ± tobacco ± spices, chewed (1) ·
Acid/base extraction of fresh young grass for tryptamines; combined with an MAOI (1) ·
Bark/woody stem decocted with a DMT-source plant (''Psychotria viridis'', ''Diplopterys cabrerana'') to make ayahuasca (1) ·
Bright red seeds, traditionally ingested or smoked. Highly toxic, narrow margin between active and lethal (1) ·
Desoxyn 5 mg tabs (1) ·
Dried leaves and twigs, infused in a gourd (''mate'') and drunk through a metal straw (''bombilla'') (1) ·
Dried leaves, infused. Six major processings: white, green, yellow, oolong, black, pu-erh (1) ·
Dried leaves; absinthe liqueur (120–160 proof, with hyssop, lemon balm, fennel, anise, sometimes Acorus calamus) (1) ·
Fermented and roasted seeds, ground. Mexican tradition: drunk with chili, cornmeal, achiote. European tradition: with sugar and milk (1) ·
Flowers or leaves infused or smoked. Highly variable potency; narrow toxic margin (1) ·
Fresh leaves and tender twigs chewed; degrades on drying (1) ·
Fresh nuts chewed; also dried and powdered (1) ·
Ground dried seed (nutmeg) or fruit aril (mace); occasionally infused (1) ·
Leaves and seeds, traditionally smoked or infused. Possibly the original Pythia oracle plant (1) ·
Leaves chewed with a pinch of slaked lime (the lime converts cocaine HCl to freebase for buccal absorption); also drunk as tea (''mate de coca'') (1) ·
Leaves, berries, root. Historically: belladonna cigarettes ("Asthmador") OTC in US until the 1970s (1) ·
Lithium carbonate: immediate-release capsules (150 mg, 300 mg, 600 mg) and tablets (300 mg); extended-release tablets (300 mg, 450 mg). Lithium citrate: oral solution (8 mEq/5 mL, equivalent to 300 mg lithium carbonate per 5 mL) for patients unable to swallow tablets. (1) ·
Parotid-gland venom expressed onto a glass plate, dried into a shellac-like resin, vaporized and inhaled (1) ·
Roasted seeds ground to powder, mixed with water; commercial syrups and energy drinks (1) ·
Root bark acid/base-extracted for DMT; or as the resurrected ''jurema preta'' brew (decocted with an MAOI such as ''Peganum harmala'') (1) ·
Root, traditionally carved into ''mannikens'' or infused into wine (1) ·
Tablets 10, 20, 40 mg; oral solution 10 mg/5 mL (1) ·
Tablets 10, 25, 50 mg (HCl); capsules 25, 50, 100 mg (pamoate); oral suspension 25 mg/5 mL; injection 25, 50 mg/mL (IM only, never IV) (1) ·
Tablets 5, 10, 20 mg; oral solution 1 mg/mL (1) ·
Toasted leaves and twigs decocted to a near-black concentrate (1)
None (412) ·
'''20 mg/day in adults >60 years''' per FDA's 2011-2012 QT-prolongation warning; 40 mg/day in adults ≤60 (1) ·
20 mg/day (adult); 10 mg/day in elderly and in hepatic impairment (1) ·
25 mg/day (ADHD per Desoxyn label); 15 mg/day (obesity, short-term, per Desoxyn label) (1) ·
28/10 mg/d (1) ·
400 mg/day theoretical; in practice rarely exceeds 200 mg/day (1) ·
No defined absolute maximum; dosing is guided by serum level monitoring. Levels above 1.5 mEq/L carry increasing toxicity risk. Levels consistently above 1.2 mEq/L are generally not maintained in clinical practice.'"`UNIQ--ref-00000052-QINU`"' (1)
None (392) ·
buccal); refined cocaine has its own profile (1) ·
inhalation (2) ·
Inhalation (vaporized) (1) ·
intramuscular (1) ·
Oral (18) ·
Oral (buccal absorption) (1) ·
Oral (buccal) (1) ·
Oral (capsule whole or opened/sprinkled on applesauce) (1) ·
Oral (leaf (1) ·
Oral (prescribed) (1) ·
Oral (with MAOI) (2) ·
smoked (extracted DMT) (1) ·
topical (1)
None (409) ·
15-30 minutes (oral) (1) ·
15–30 min (2) ·
Antidepressant effect emerges over 1-2 weeks; full clinical effect 4-6 weeks (1) ·
Antidepressant effect over 1-2 weeks; full clinical effect 4-6 weeks (1) ·
Antimanic effects begin within 5-7 days of reaching therapeutic serum levels, with full response often requiring 2-3 weeks. For acute mania, a neuroleptic is typically added for rapid sedation while lithium takes effect.'"`UNIQ--ref-00000053-QINU`"' (1) ·
Component effects accumulate over weeks (1) ·
Seconds (1) ·
Slow, 2–6 h (1)
None (411) ·
14-25 hours (longer in elderly and hepatic impairment)'"`UNIQ--ref-00000026-QINU`"' (1) ·
27-32 hours'"`UNIQ--ref-00000026-QINU`"' (1) ·
9–12 minutes (intravenous) (1) ·
Approximately 18-24 hours after acute administration; may extend to 36-48 hours with chronic dosing as tissue compartments equilibrate. Serum trough levels should be drawn 12 hours after the last dose for accurate interpretation.'"`UNIQ--ref-00000055-QINU`"' (1) ·
~35 hours'"`UNIQ--ref-00000026-QINU`"' (1) ·
~5 h (caffeine) (1) ·
~60–80 h (memantine); ~70 h (donepezil) (1)
None (414) ·
Category C (per Desoxyn label) (1) ·
Limited human data; older agent with substantial use experience; some signal for first-trimester exposure but not conclusive.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Not relevant (geriatric problem) (1) ·
Observational signal for persistent pulmonary hypertension of the newborn (small absolute risk) and neonatal adaptation syndrome with third-trimester exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
None (406) ·
5-MeO-DMT is Schedule I in US (since 2011); the toad itself is protected in several southwestern states (1) ·
Currently legal in most jurisdictions with thujone limits (1) ·
Leaves legal in Bolivia, Peru, Colombia; cocaine internationally controlled (1) ·
Not a controlled substance in the United States, European Union, United Kingdom, Canada, or Australia. Prescription-only in all of these jurisdictions due to the narrow therapeutic index and the need for serum monitoring. No abuse potential has been identified. (1) ·
Plant unrestricted; pharmaceutical atropine Rx-only (1) ·
Rx-only in US (1) ·
Schedule I in US since 1993 (despite traditional use elsewhere); legal in Ethiopia, Kenya, Yemen, Somalia, Djibouti (1) ·
Schedule II (1) ·
[[USLegal:DEA Schedule I|Schedule I]] (United States) (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-00000028-QINU`"' (2) ·
[[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, which is a meaningful clinical advantage over the benzodiazepine alternatives for short-term anxiety'"`UNIQ--ref-00000028-QINU`"' (1)
Error in "where" parameter: the string "--" cannot be used within #cargo_query.
There are no results for this report.

